Photo of Kim-Hien T. Dao, DO, PhD

Kim-Hien T. Dao DO, PhD

Dr. Kim-Hien Dao received her post-doctoral internal medicine training at Scripps Mercy Hospital in San Diego, California, and her hematology/oncology fellowship training at the University of California, San Diego. Dr. Dao started her position as an assistant professor in the Division of Hematology and Oncology, Center for Hematologic Malignancies at OHSU in the fall of 2009. She is a member of the OHSU Knight Cancer Institute. She sees patients who have damage to the blood-forming cells in their bone marrow (myelodysplastic syndrome) or myelodysplastic syndrome that has transformed into acute myelogenous leukemia. She works with other scientists on several clinical trials (research studies), and plans to start her own clinical trials of new treatments for patients with myelodysplastic syndromes that are very likely to become leukemia. She spends much of her day in the laboratory, studying how blood diseases become leukemia. Dr. Dao hopes her research will help develop treatments to stop the development of leukemia.

Education

  • Ph.D., Michigan State University, 0 0 2002
  • B.S., Michigan State University, East Lansing Michigan 0 2002
  • Residency:

    • Internal medicine, Scripps Mercy Hospital, 2006
  • Fellowship:

    • Hematology/oncology, University of California, San Diego, 2009
  • Certifications:

    • American Board of Internal Medicine (internal medicine), 2006

Memberships and associations

  • American Society of Hematology

Publications

  • "Myelodysplastic Syndromes : Updates and Nuances." Medical Clinics of North America  In: , Vol. 101, No. 2, 01.03.2017, p. 333-350.
  • "Polycythemia Vera Management and Challenges in the Community Health Setting." Oncology (Switzerland)  In: , 18.01.2017.
  • "Clonal hematopoiesis as determined by the HUMARA assay is a marker for acquired mutations in epigenetic regulators in older women." Experimental Hematology  In: , Vol. 44, No. 9, 01.09.2016, p. 857-865.e5.
  • "A phase II study of the efficacy, safety, and determinants of response to 5-azacitidine (Vidaza®) in patients with chronic myelomonocytic leukemia." Leukemia and Lymphoma In: , 05.02.2016, p. 1-4.
  • "Mutant calreticulin-expressing cells induce monocyte hyperreactivity through a paracrine mechanism." American Journal of Hematology  In: , Vol. 91, No. 2, 01.02.2016, p. 211-219.
  • "Age-related mutations and chronic myelomonocytic leukemia." Leukemia In: , 09.12.2015.
  • "What's different about atypical CML and chronic neutrophilic leukemia?" Hematology In: , Vol. 2015, No. 1, 05.12.2015, p. 264-271.
  • "Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia." Leukemia Research Reports In: , Vol. 3, No. 2, 01.01.2015, p. 67-69.
  • "The PI3K/Akt1 pathway enhances steady-state levels of FANCL." Molecular Biology of the Cell In: , Vol. 24, No. 16, 15.08.2013, p. 2582-2592.
  • "Next-generation medicine : Combining BCR-ABL and hedgehog-targeted therapies." Clinical Cancer Research In: , Vol. 19, No. 6, 15.03.2013, p. 1309-1311.
  • "A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition." Cell Stem Cell  In: , Vol. 12, No. 3, 07.03.2013, p. 316-328.
  • "ADAR1 promotes malignant progenitor reprogramming in chronic myeloid leukemia." Proceedings of the National Academy of Sciences of the United States of America  In: , Vol. 110, No. 3, 15.01.2013, p. 1041-1046.
  • "FANCL ubiquitinates β-catenin and enhances its nuclear function." Blood In: , Vol. 120, No. 2, 12.07.2012, p. 323-334.
  • "BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib." Blood In: , Vol. 116, No. 17, 28.10.2010, p. 3278-3285.
  • "Rac1 and Cdc42 are regulators of HRasV12-transformation and angiogenic factors in human fibroblasts." BMC Cancer  In: , Vol. 10, 13, 12.01.2010.
  • "Glycogen synthase kinase 3β missplicing contributes to leukemia stem cell generation." Proceedings of the National Academy of Sciences of the United States of America  In: , Vol. 106, No. 10, 10.03.2009, p. 3925-3929.
  • "Pyoverdine production by Pseudomonas aeruginosa exposed to metals or an oxidative stress agent." Ecological Applications In: , Vol. 9, No. 2, 1999, p. 441-448.

Additional information

Edit profile